Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MPS I). Funding source -- FDA OOPD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

NCT00786968

Spinal Cord Compression Mucopolysaccharidosis I Hurler-Scheie Syndrome +2 more

TERMINATED PHASE1

Longitudinal Study of Bone Disease in Children with Mucopolysaccharidoses (MPS) I, II, and VI

NCT01521429

Mucopolysaccharidoses

COMPLETED

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

NCT00146757

Mucopolysaccharidosis I Hurler Syndrome Hurler-Scheie Syndrome +1 more

COMPLETED PHASE2

Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I

NCT02232477

Mucopolysaccharidosis I Cognitive Decline

TERMINATED NA

Intrathecal Enzyme Replacement for Hurler Syndrome

NCT00638547

Hurler Syndrome

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Enzyme replacement therapy (ERT) has been developed for mucopolysaccharidosis I (MPS I), a lysosomal storage disorder. ERT helps many physical ailments due to the disease, but does not treat the central nervous system, due to inability to cross the blood brain barrier. Our purpose is to test delivery of ERT to the spinal fluid via intrathecal injection in patients with MPS I. In this pilot study, we will use recombinant human α-L-iduronidase administered intrathecally once per month for four months to individuals with the Hurler-Scheie and Scheie forms of MPS I and spinal cord compression. If successful, intrathecal delivery could represent a practical, straightforward method of treating central nervous system disease due to lysosomal storage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mucopolysaccharidosis I Lysosomal Storage Diseases Spinal Cord Compression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intrathecal laronidase

laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months

Group Type EXPERIMENTAL

laronidase

Intervention Type DRUG

0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

laronidase

0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aldurazyme

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hurler-Scheie,Scheie form of MPS I, of Hurler 2 years after hematopoietic stem cell transplantation
* Spinal cord compression
* Age greater than 8 years
* Able to provide legal informed consent
* Aware of clinical treatment option of observation without treatment or surgical decompression
* Negative urine pregnancy test at screening (non-sterile females of child-bearing potential only)
* Currently using two acceptable methods of birth control (non-sterile females of child-bearing potential who are sexually active only)
* Willing and able to comply with study procedures

Exclusion Criteria

* Severe (Hurler) form of MPS I
* Desires surgical or medical treatment of spinal cord compression
* Spinal cord compression that warrants immediate surgical intervention
* Pregnancy or lactation
* Hematopoietic stem cell transplantation within 2 years of study enrollment
* Receipt of an investigational drug within 30 days of enrollment
* Infusion reactions to laronidase that required medical intervention, prophylaxis, or altered enzyme administration
* Significant anti-iduronidase antibody titer
* Recent initiation of intravenous laronidase (within past 6 months)
* Presence of cervical subluxation or similar external pathology as the major cause of cord compression symptoms for which surgical intervention should be immediately undertaken

Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No